Arezou Zoroufian1. 1. Assistant Professor of Cardiology, Department of Cardiology, Tehran Heart Center, North Kargar Street, Tehran, Iran, 1411713138, Tel: +98 21 88029256, , E-mail: arezou.zoroufian@yahoo.com.
We appreciate Dr. H. Sadeghian’s well-advised comments on our paper, entitled “Tricuspid regurgitation improvement in relation to the amount of pulmonary artery pressure reduction”.1 Dr. H. Sadeghian expresses concerns regarding the conclusions of the paper and the definition of pulmonary artery hypertension.This study was aimed, as the manuscript title clearly reflects, to analyze whether the amount of changes in pulmonary artery systolic pressure (PAPs) can affect the changes in tricuspid regurgitation severity. It is well established that pulmonary hypertension is an important cause of functional tricuspid regurgitation and PAPs is a strong determinant of functional tricuspid regurgitation (TR) severity.2, 3 In addition, right ventricle dilation and dysfunction may result in functional TR, and functional TR can secondarily be associated with left ventricle dysfunction and mitral valve disease (both mitral stenosis and regurgitation).4–6 We studied a sample of patients with mitral stenosis who underwent mitral balloon valvoplasty (MBV). Our analysis was on the basis of the fact that in these patients, functional TR has been a consequence of increased PAPs secondary to severe mitral stenosis; the higher the severity of mitral stenosis (MS), the higher the PAPs and the higher the severity of TR grade. The increased PAPs is expected to decline following MBV. In the mentioned study, we presented a possible cut-off point for the amount of PAPs reduction showing TR severity improvement; and the ROC (receiver-operating characteristic) analysis, which demonstrated a cut-off point of ≥ 19 mmHg reduction in PAPs with a 71.9% specificity and 52.7% sensitivity, might show at least a one-grade regress in TR severity.1 It is deserving of note that we did not claim that we would aim either to identify the predictors of TR improvement or to find out the factors in association with PAPs. It is obvious that the determination of the predicting factors for the improvement of TR severity or the factors associated with increased PAPs (none of them was the aim of this study) requires a large sample size. Hopefully in the near future with a large study population, we will be able to present all the potential predicting factors for TR severity improvement in patients suffering from TR for any reasons, not just organic MS and its severity (our biostatistician whose name is revered amongst the co-authors approved the above remarks). We believe that Dr. H. Sadeghian is also aware that factors such as initial MS grade, mitral valve area, and MS severity change all affect TR severity improvement through changes in the pulmonary artery pressure and no one can claim that these factors directly affect the tricuspid valve in the right heart side.With respect to pulmonary artery hypertension, we agree that in the references cited in the paper, PAPs > 35 mmHg is defined as elevated PAPs. We found it reasonable to use this cut point to define pulmonary artery hypertension in the same manner as many other studies.7–10 We would believe that if every investigator is restricted to define the study variables as guidelines, no new findings and conclusions can be added to our knowledge and future guidelines. In this study, we grouped the patients based on PAPs > 35 mmHg so as to report only the frequency of the patients with pulmonary artery hypertension. We applied PAPs as a continuous variable in determining the cut-off value of the amount of PAPs reduction in relation with TR severity improvement, which means that even changing the definition would not influence the achieved cut-off point.Finally, we should stress that all the patients with right ventricular dysfunction were excluded from the study. Also, no difference was found between the men and women regarding changes in PAPs and TR severity. These should have been mentioned in the method section, and we are grateful to have the opportunity to explain it in this reply.We hope these lines will allow the esteemed readers to better understand the views mentioned.
Authors: M V Mogollón Jiménez; A M Escoresca Ortega; M L Cabeza Letrán; R Hinojosa Pérez; E Lage Gallé; J M Sobrino Márquez; A Herruzo Avilés; N Romero Rodríguez; M Frutos López; R Pérez de la Yglesia; A Martínez Martínez Journal: Transplant Proc Date: 2008-11 Impact factor: 1.066
Authors: Robert O Bonow; Blase A Carabello; Chatterjee Kanu; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-08-01 Impact factor: 29.690
Authors: Frank Lloyd Dini; Piercarlo Ballo; Luigi Badano; Paolo Barbier; Piersilvio Chella; Umberto Conti; Salvatore Mario De Tommasi; Maurizio Galderisi; Stefano Ghio; Enrico Magagnini; Andrea Pieroni; Andrea Rossi; Cesare Rusconi; Pier Luigi Temporelli Journal: Eur J Echocardiogr Date: 2010-04-17